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Background: Several signaling pathways are interrelated in platelet aggregation processes. Cangrelor is a selective intravenous inhibitor of platelet 
P2Y12 receptor with potent and reversible effects. The aim of this study was to assess the impact of cangrelor-induced inhibitory effects on different 
platelet signaling pathways.
Methods: Platelet reactivity was evaluated in 80 clopidogrel naïve patients on aspirin therapy with the Multiplate Analyzer following stimuli 
with P2Y12 specific [adenosine diphosphate (ADP), ADP + prostaglandin E1 (PGE)] and non-specific [arachidonic acid (AA), collagen (COLL) and 
thrombin receptor activated peptide (TRAP)] agonists, at baseline and after in vitro incubation with cangrelor (500 nM). Results are expressed as 
area under the curve of arbitrary units (AU*min). Absolute and relative changes in platelet aggregation were calculated for each agonist.
Results: A marked decrease in the absolute change of platelet aggregation was observed with all agonists (ADP: 533 [95% CI: 481-586] AU*min; 
ADP+PGE: 216 [95% CI: 345-441]; AA: 218 [95%CI: 162-275] AU*min; COLL: 258 [95%CI: 217-298]; TRAP: 532 [95% CI: 484-581] AU*min; 
p<0.001 for each comparison). Accordingly, cangrelor was associated with a marked increase in the relative change, expressed as percentage of 
platelet inhibition (Figure). 
Conclusions: Cangrelor induces potent platelet inhibitory effects, which are mediated by the P2Y12 receptor as well as by other pivotal platelet 
signaling pathways.
